Stockscreener 앱 받기
10.79
5.85%
-0.67
전일 마감가:
$11.46
열려 있는:
$11.51
하루 거래량:
4.06M
Relative Volume:
0.84
시가총액:
$1.12B
수익:
$45.97M
순이익/손실:
$-508.80M
주가수익비율:
-1.969
EPS:
-5.48
순현금흐름:
$-382.65M
1주 성능:
-6.09%
1개월 성능:
-2.97%
6개월 성능:
+10.21%
1년 성능:
-51.79%
1일 변동 폭
$10.57
$11.51
1주일 범위
$10.57
$12.30
52주 변동 폭
$5.90
$24.16
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
NTLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
10.79 | 1.18B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript - MSN
Intellia Therapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Analysts Have Lowered Expectations For Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results - 富途牛牛
Wells Fargo Maintains Overweight on Intellia, PT Down to $45 - AInvest
Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus - Yahoo Finance
Intellia Therapeutics stock price target lowered to $45 by Wells Fargo - Investing.com Canada
Leerink Partners lowers Intellia Therapeutics stock price target to $41 By Investing.com - Investing.com Canada
Intellia: HC Wainwright Keeps Buy Rating, Lowers PT to $25 from $30. - AInvest
Gene-Editing's Quiet Revolution: Why Intellia Therapeutics Could Redefine Rare Disease Investing - AInvest
INTELLIA THERAPEUTICS, INC. (NTLA) - MSN
Intellia (NTLA) Q2 Revenue Jumps 106% - AOL.com
Intellia Therapeutics Inc (NTLA) Q2 2025 Earnings Call Highlights: Strategic Advancements and Financial Resilience - GuruFocus
Intellia Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Intellia Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Intellia Therapeutics' Momentum in ATTR-CM and HAE Trials: A Catalyst-Driven Path to First-Time Commercial Success - AInvest
Intellia Therapeutics' Q2 2025: Key Contradictions in MERIT Trial Expansion, Cash Runway, and Clinical Study Timelines - AInvest
RBC Cuts Price Target on Intellia Therapeutics to $21 From $25, Keeps Outperform Rating - MarketScreener
Intellia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Intellia Therapeutics beats Q2 2025 forecasts - Investing.com India
Transcript : Intellia Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Intellia Therapeutics Announces Executive Retirement - TipRanks
Intellia Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com Australia
Intellia Therapeutics Announces Second Quarter 2025 Financial Re - GuruFocus
Earnings Flash (NTLA) Intellia Therapeutics Posts Q2 Net Loss $0.98 a Share, vs. FactSet Est of $1.02 Loss - MarketScreener
Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q2 Revenue $14.2M, vs. FactSet Est of $11.9M - MarketScreener
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Intellia Reports 98% HAE Attack Reduction in 3-Year Data, Accelerates Phase 3 Enrollment Across Programs - Stock Titan
Intellia Therapeutics shares rise 6.61% intraday as Wall Street recovers from Friday's selloff. - AInvest
How many analysts rate Intellia Therapeutics Inc. as a “Buy”Explosive returns - Jammu Links News
Is Intellia Therapeutics Inc. stock overvalued or undervaluedAchieve rapid wealth accumulation with smart picks - Jammu Links News
What are Intellia Therapeutics Inc. company’s key revenue driversMaximize gains with proven stock analysis - Jammu Links News
What is Intellia Therapeutics Inc. company’s growth strategyTriple-digit return opportunities - Jammu Links News
Why is Intellia Therapeutics Inc. stock attracting strong analyst attentionUnmatched profit potential - Jammu Links News
When is Intellia Therapeutics Inc. stock expected to show significant growthDiscover market opportunities with expert help - Jammu Links News
What is the dividend policy of Intellia Therapeutics Inc. stockAccelerated financial growth - Jammu Links News
Does Intellia Therapeutics Inc. stock perform well during market downturnsMaximize gains with proven stock analysis - Jammu Links News
What makes Intellia Therapeutics Inc. stock price move sharplyUnlock daily market insights for better decisions - Jammu Links News
How does Intellia Therapeutics Inc. compare to its industry peersFree Predictions - Jammu Links News
What catalysts could drive Intellia Therapeutics Inc. stock higher in 2025Breakout portfolio performance - Jammu Links News
Intellia Therapeutics Offers Inducement Grants Amidst Employment Expansion Amidst Challenges in Financial Health and Business Performance - AInvest
Intellia Therapeutics Awards Inducement Grants to New Employees - AInvest
Crispr Therapeutics shares rise 1.18% after-hours following Intellia Therapeutics' inducement grants announcement. - AInvest
Price Action Confirms Reversal in Intellia Therapeutics Inc. TrendFast Exit and Entry Strategy Guide Offered - metal.it
NTLA Awards Inducement Grant Amid Employment Expansion - GuruFocus
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - AInvest
Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus
Intellia Therapeutics Awards Inducement Grants to New Employees. - AInvest
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Expands Team with Strategic Stock Grants Worth 18,200 Shares - Stock Titan
Intellia Therapeutics shares fall 4.12% premarket ahead of Q2 2025 earnings call. - AInvest
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):